Traws Pharma, Inc. (NASDAQ:TRAW) is a pharmaceutical company currently trading at $1.61. However, with a target price of $0.73, it faces a potential downside of approximately -54.90%. This significant negative growth potential has led investment analysts to exclude Traws from coverage, reflecting a pessimistic outlook on the stock.
In comparison, Imunon, Inc. (IMNN) presents a more optimistic scenario. With a current price of $3.80 and a target price of $5.36, Imunon has a growth potential of +41.18%. Despite a negative earnings per share (EPS) of -12.53 and a price-to-earnings (P/E) ratio of -0.68, its market cap stands at $9.58 million, indicating investor interest.
Cocrystal Pharma, Inc. (COCP) is another peer, trading at $1.11 with a target price of $0.79, suggesting a growth potential of -28.68%. Its market cap is $11.38 million, with an EPS of -0.93 and a P/E ratio of -1.17, reflecting challenges similar to Traws.
Mustang Bio, Inc. (MBIO) trades at $1.09 with a target price of $0.97, resulting in a growth potential of -10.76%. With a market cap of $7.96 million, an EPS of -6.71, and a P/E ratio of -3.44, it faces moderate challenges compared to its peers.
